Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q1 Loss of 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts NBIX Hot Sheet
Price: $141.81 -1.03%
EPS Growth %: -12.0%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -12.0%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q1 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $10.84 million.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-powered cyber threats light a fire under cybersecurity stocks
- Lockheed Martin (LMT) PT Raised to $692 at UBS
- Venture Global rises after QatarEnergy supply talks reported
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
